Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis.

Hufnagel HR, Tennyson SD.

Open source

DOI
10.1080/14712598.2024.2376197
Published
2024-07-04
Container
Expert Opin Biol Ther
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14712598.2024.2376197,
  title = {Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis.},
  author = {Hufnagel HR and  Tennyson SD.},
  year = {2024},
  journal = {Expert Opin Biol Ther},
  doi = {10.1080/14712598.2024.2376197},
  url = {https://doi.org/10.1080/14712598.2024.2376197}
}

RIS

TY  - JOUR
TI  - Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis.
AU  - Hufnagel HR
AU  -  Tennyson SD.
PY  - 2024
JO  - Expert Opin Biol Ther
DO  - 10.1080/14712598.2024.2376197
UR  - https://doi.org/10.1080/14712598.2024.2376197
ER  - 

APA

HR, H., & SD., T. (2024). Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis.. Expert Opin Biol Ther. https://doi.org/10.1080/14712598.2024.2376197

Source records